An RP-HPLC purity number is the main peak’s share of the total peak area in one chromatogram, recorded at one detection wavelength under one method.
It measures how cleanly the main component separates from the other material the detector can see. It does not measure how much peptide is in the vial, and on its own it does not prove which peptide it is.
RP-HPLC purity is the figure most readers look at first on a certificate of analysis, and the one most often read as more than it is. This article explains how the number is calculated, what it leaves out, and what should sit next to it on a well built certificate. For the certificate as a whole, see our guide to reading a certificate of analysis without guessing.
Scope: this is an explainer on analytical methods for laboratory readers. How Iron Rack Labs materials are supplied is set out in the research use policy.
How an RP-HPLC purity figure is calculated
Reversed-phase high performance liquid chromatography pushes a dissolved sample through a column packed with a nonpolar stationary phase. Components leave the column at different times depending on how strongly they interact with it, and a detector records each one as a peak. The purity figure is then worked out by area normalization. The harmonized USP general chapter on chromatography describes that procedure as the area of one peak taken as a percentage of the total area of all peaks, excluding peaks from solvents, reagents, the mobile phase or the sample matrix.
Retention time
The time a component takes to leave the column. Two different molecules can have retention times so close that their peaks overlap.
Peak area
The integrated detector signal for one peak. It depends on how much material is present and on how strongly that material absorbs at the chosen wavelength.
Area percent
One peak’s area divided by the summed area of every counted peak. It is a ratio inside one chromatogram, not a weight.
Peptides are usually detected by ultraviolet absorbance at a low wavelength, where the peptide bond itself absorbs. The response is not the same for every molecule. Kuipers and Gruppen measured molar extinction coefficients at 214 nm and reported a value of 923 per molar per centimeter for the peptide bond, with tryptophan roughly 30 times higher and phenylalanine, tyrosine and histidine roughly six times higher. An impurity that gains or loses one of those residues therefore gives a peak that is larger or smaller than its true share of the material. Area percent quietly assumes an equal response for every peak, and that assumption is only approximately true.
Is a purity figure the amount of peptide in the vial?
No. The figure is a ratio among the things the detector saw. Anything the detector does not see, or that the method deliberately excludes, is outside the calculation entirely.
Purity asks what share of the detected peaks belongs to the target. Content asks what share of the weighed powder is the target peptide. They are separate questions, answered by separate tests.
- Counterions are not in the purity figure. Synthetic peptides are commonly supplied as salts. A structured review of peptide impurities by D’Hondt and colleagues notes that counterions such as trifluoroacetate, left from synthesis or purification, can remain in the final material. They add weight to the powder without adding a peptide peak.
- Water is not in the purity figure. Lyophilized peptides can hold residual moisture, which is measured by a separate method, if it is measured at all.
- Salts and solvents without a chromophore are invisible. A component that does not absorb at the detection wavelength produces no peak, so it cannot lower the area percent.
- Content is a separate calculation. Reconciling purity with water, counterion and other results is known as mass balance, an approach discussed for therapeutic peptides in a 2025 review of mass balance by Hetrick and colleagues. A purity figure is one input to that picture, not the picture itself.
What a chromatogram can miss
Two things follow from the method that are widely misunderstood. The first is that a clean looking chromatogram only shows what the method can separate. The second is that separation has to be demonstrated, not assumed.
Validation guidance draws exactly this line. The ICH Q2(R2) guidance on validation of analytical procedures, issued by FDA in March 2024, describes specificity and selectivity as the extent to which other substances interfere with the determination of an analyte. For critical separations in chromatography, it states that specificity can be shown by the resolution of the two components that elute closest to each other, and that a result can also be verified against a second, well characterized procedure.
Peptide synthesis produces exactly the kind of close relatives that test resolution. The D’Hondt review groups them into impurities from synthesis, such as amino acid deletions and insertions, diastereomers from racemization, side chain oxidation and dimers, and impurities from degradation, such as pyroglutamate, diketopiperazine and succinimide formation. A diastereomer has the same mass as the target and can sit very close to it on the column. If the two peaks merge, the impurity is counted as target and the purity figure goes up, not down. Degradation after testing matters too, which is why our article on cold chain and storage temperature treats handling as part of the analytical story.
How regulators set the bar for drug peptides
For generic versions of five synthetic peptide drugs, FDA guidance published in May 2021 says applicants should identify each peptide related impurity at 0.10 percent of the drug substance or greater, and recommends sensitive, high resolution procedures such as UHPLC with high resolution mass spectrometry. That guidance covers specific drug applications. It is cited here for what it shows about method sensitivity: regulators treat a single UV chromatogram as the start of an impurity assessment, not the end of it.
What an RP-HPLC purity number does not establish
A purity figure is useful, but it answers a narrow question. These are the questions it leaves open.
- Identity. A tall main peak shows that one component dominates. It does not show which component. Identity needs a separate test, usually mass spectrometry, read against the expected mass for the stated sequence. Our profile of BPC-157 shows how a sequence and its expected mass are stated.
- Net peptide content. As above, water, counterions and other non detected material sit outside the ratio.
- The identity of the other peaks. Area percent reports how much of the signal is not the main peak. It does not say what those peaks are.
- Performance under another method. Change the column, gradient or wavelength and the separation changes. A figure is tied to the conditions that produced it.
- Another lot. A chromatogram describes the sample that was injected. It says nothing about material made on another day.
Reading the purity line on a certificate
A purity figure is only as useful as the information printed next to it. Pharmacopeial practice describes peptide quality as a set of attributes rather than one number: USP publishes a general chapter dedicated to quality attributes of synthetic peptide drug substances. On a certificate for research material, each result should be tied to a method, a lot and a date. Check that the purity line carries the following.
- Method named as RP-HPLC, with the column type stated
- Detection wavelength stated
- Chromatogram attached, with integrated peaks visible
- Purity reported for one specific lot number
- Lot number on the certificate matches the vial label
- Identity reported separately, as measured mass against expected mass
- Testing laboratory and test date identified
- Salt form or counterion stated
A certificate that reports a purity figure with no method, no chromatogram and no lot number gives the reader nothing to check. Iron Rack Labs publishes lot matched certificates in the certificate of analysis library, and the quality and testing page explains which tests are run on each lot. Pick any lot record there and read it against the list above.
- RP-HPLC purity is the main peak’s share of total detected peak area
- It is tied to one method, one wavelength and one lot
- Water, counterions and non absorbing material sit outside it
- Close impurities can merge with the main peak and inflate it
- Identity and content need separate tests
Frequently asked questions
RP-HPLC purity is the area of the main peak expressed as a percentage of the total area of all counted peaks in one reversed-phase chromatogram. It is calculated by area normalization at a single detection wavelength. It describes how cleanly the main component separates from other detected material under that method, not the weight of peptide in the sample.
No. Purity is a ratio of peak areas among the components the detector can see. Peptide content is the share of the weighed powder that is the target peptide. Water, counterions such as trifluoroacetate and other material that does not absorb at the detection wavelength add weight without adding a peak, so content is measured by separate tests.
Yes. The figure depends on the column, the gradient, the detection wavelength and how peaks are integrated. A method with better resolution may separate an impurity that another method merges into the main peak, which lowers the reported purity. That is why a purity figure should always be read together with the method and conditions that produced it.
No. A high figure shows that one component dominates the chromatogram, not which component it is. A different peptide, or the right sequence with a changed residue, can give a clean single peak. Identity is confirmed separately, usually by mass spectrometry read against the expected mass for the stated sequence.
It should name the method, the column type and the detection wavelength, attach the chromatogram, and tie the result to one lot number and test date. The certificate should also report identity separately and state the salt form. Without a method, a chromatogram and a lot number, a purity figure cannot be checked by the reader.
- USP General Chapter <621>, Chromatography. Harmonized standard, official December 1, 2022. United States Pharmacopeia, 2022. View source
- Kuipers BJ, Gruppen H, 2007. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. Journal of Agricultural and Food Chemistry, 55(14), 5445 to 5451. DOI
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B, 2014. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis, 101, 2 to 30. DOI
- Hetrick EM, Pack BW, Wolfe CN, Zhao M, 2025. Mass balance analysis for therapeutic peptides: case studies, applications, and perspectives. Journal of Pharmaceutical and Biomedical Analysis, 252, 116501. DOI
- Q2(R2) Validation of Analytical Procedures, Guidance for Industry. U.S. Food and Drug Administration, March 2024. View source
- ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, Guidance for Industry. U.S. Food and Drug Administration, May 2021. View source
- USP General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances. United States Pharmacopeia, 2021. View source
